ABVX ABIVAX Société Anonyme

NASDAQ
$118.96

ABIVAX Société Anonyme (ABVX) is confirmed to report earnings on September 21, 2026, after the market close. The consensus earnings estimate is a loss of $1.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.1% since its last earnings release on May 22, 2026.

ABIVAX Société Anonyme Beat Consensus Estimates
Friday, May 22, 2026 · 4:05 PM ET
Earnings Date
2nd Quarter, Jun 2026
Sep 21
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($1.08)
Rev est $1.86M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $111.30

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ABIVAX Société Anonyme

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases

Sector

Healthcare

Industry

Biotechnology